Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
01 2019
Historique:
received: 29 12 2017
revised: 29 09 2018
accepted: 01 10 2018
pubmed: 24 10 2018
medline: 18 12 2019
entrez: 24 10 2018
Statut: ppublish

Résumé

Radiotherapy treatment plan quality can influence clinical trial outcomes and general QA may not identify suboptimal organ-at-risk (OAR) sparing. We retrospectively performed patient-specific quality assurance (QA) of 100 head-and-neck cancer (HNC) plans from the EORTC-1219-DAHANCA-29 study. A 177-patient RapidPlan (Varian Medical Systems) model comprising institutional HNC plans was used to QA trial plans (P OAR predictions were made within 2 min per patient. Averaged PG/SMG/SM mean doses were 2.0/9.0/3.8 Gy lower in P Individualized QA indicated that OAR sparing could frequently be improved in EORTC-1219 study plans, even though they met the trial's generic plan criteria. Automated, patient-specific QA can be performed within a few minutes and should be considered to reduce the influence of planning variation on trial outcomes.

Identifiants

pubmed: 30348462
pii: S0167-8140(18)33510-2
doi: 10.1016/j.radonc.2018.10.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-81

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Jim P Tol (JP)

VU University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands. Electronic address: j.tol.vumc@gmail.com.

Max Dahele (M)

VU University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands.

Vincent Gregoire (V)

Université catholique de Louvain, St-Luc University Hospital, Experimental and Clinical Research Institute, Center for Molecular Imaging, Oncology and Radiotherapy, Brussels, Belgium.

Jens Overgaard (J)

Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark.

Ben J Slotman (BJ)

VU University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands.

Wilko F A R Verbakel (WFAR)

VU University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands. Electronic address: w.verbakel@vumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH